Surely wasn't this week. Again, more of the same f

Surely wasn't this week. Again, more of the same from this suspect OTC company that has a very suspect CEO that only has success in draining the companies he runs and massively increasing its share count. Its new President has, so far, been unsuccessful in bringing in financial partners or moving its pipeline into the clinics. As such, the pps continues to drop